IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts

BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.